Patients with chronic HCV often have cross-reactive neutralizing agents but are unable to clear the virus, possibly because the HCV virions are able to avoid lysis. A study has shown that cultured HCV particles incorporate host CD59, a regulator of lysis by complement activation, into their cell membrane. These virions were able to resist antibody-dependent complement-mediated lysis. Addition of CD59 blockers to the culture reversed this phenomenon.